A treatment that extends life by a meaningful margin in a disease where every month matters
At the 2026 ASCO conference, researchers presented evidence that ivonescimab — a bispecific antibody developed by Akeso and Summit Therapeutics — reduced the risk of death by 34 percent in patients with advanced squamous cell lung cancer when added to chemotherapy, outperforming the current standard of care. In a disease that claims nearly two million lives each year, this margin is not a statistical footnote but a human one, measured in months returned to people who had few left. The result settles a long-running debate within oncology and places a new contender at the center of a field that has spent a decade building its hopes on PD-1 inhibition.
- Squamous cell lung cancer — aggressive, poorly responsive, and responsible for roughly a quarter of all lung cancer deaths — has long resisted meaningful improvement in survival outcomes.
- Ivonescimab's 34% mortality reduction over standard PD-1-plus-chemotherapy regimens is a result large enough to unsettle existing treatment hierarchies and demand a response from the global oncology community.
- The drug already holds approval in China, where the trial was conducted, but patients in the United States and Europe remain in a regulatory waiting room while their oncologists weigh evidence they cannot yet act on.
- Regulatory agencies, health systems, and clinicians must now navigate questions of approval timelines, population generalizability, manufacturing scale, and cost before this survival benefit reaches patients beyond China's borders.
- The ASCO presentation has effectively shifted the burden of proof — the question is no longer whether ivonescimab works, but how quickly the world will let it work for everyone.
At the 2026 American Society of Clinical Oncology conference, researchers unveiled late-stage trial results for ivonescimab, a drug developed by Chinese biotech Akeso in partnership with Summit Therapeutics, that could fundamentally alter how oncologists approach squamous cell lung cancer. When combined with chemotherapy, ivonescimab reduced the risk of death by 34 percent compared to the current standard — chemotherapy paired with a PD-1 inhibitor — a margin that carries real weight in a disease killing roughly 1.8 million people annually.
The result matters in part because it resolves a genuine scientific dispute. Ivonescimab targets a different immune pathway than PD-1 inhibitors, and while some researchers believed this mechanism held promise, skepticism persisted. The new data moved the argument from theory to evidence. PD-1 inhibitors have become the backbone of modern lung cancer treatment over the past decade, so demonstrating that ivonescimab can outperform them is not a minor refinement — it is a challenge to the reigning standard of care.
The trial focused specifically on patients with advanced squamous cell lung cancer, a particularly aggressive variant that accounts for about a quarter of all lung cancer cases and has historically offered patients limited options and poor prognoses. For this population, a 34 percent reduction in mortality translates directly into extended survival in a context where every additional month is significant.
Ivonescimab has already received approval in China, where the trial was conducted, and the ASCO presentation strengthens the case for broader adoption. But oncologists in the United States and Europe face a gap between the evidence now in front of them and the regulatory approvals that would allow them to act on it. Questions about how the drug performs in Western populations, its cost, and manufacturing capacity will all shape how quickly and widely it enters global practice. What the conference established clearly is that, for the patients studied, ivonescimab represents a measurable step forward in a disease that has long demanded one.
At the American Society of Clinical Oncology conference in 2026, researchers presented results from a late-stage clinical trial that could reshape how doctors treat one of the deadliest forms of lung cancer. The drug in question, ivonescimab, made by the Chinese biotech company Akeso in partnership with Summit Therapeutics, reduced the risk of death by 34 percent when combined with chemotherapy compared to the standard approach of pairing chemotherapy with a PD-1 inhibitor alone. The trial focused on squamous cell lung cancer, a particularly aggressive variant that accounts for roughly a quarter of all lung cancer cases worldwide.
The significance of this result lies partly in what it settles. Ivonescimab has been a subject of genuine scientific debate in oncology circles—some researchers believed the drug's mechanism held promise, while others remained skeptical. The new data from the Chinese trial provides the kind of hard evidence that moves skeptics. Patients who received ivonescimab alongside chemotherapy lived longer than those who received chemotherapy with a conventional PD-1 inhibitor, a comparison that matters because PD-1 inhibitors have become the backbone of modern lung cancer treatment. A 34 percent reduction in mortality is not marginal; it represents a meaningful extension of survival for people facing a disease that kills roughly 1.8 million people annually worldwide.
The trial enrolled patients with advanced squamous cell lung cancer, the subset of the disease most difficult to treat effectively. These patients typically have limited options and poor prognoses. By demonstrating that ivonescimab could outperform the existing standard of care, the researchers showed that there remains room for improvement even in a treatment landscape that has already advanced considerably over the past decade. The mechanism behind ivonescimab differs from PD-1 inhibitors; it targets a different pathway in the immune system, which may explain why combining it with chemotherapy produced better results than the conventional pairing.
The presentation at ASCO, one of the world's largest cancer research conferences, signals that these findings will likely influence treatment decisions globally. Oncologists in the United States and Europe will now face questions about whether to adopt ivonescimab for their own patients, though regulatory approval in those regions remains pending. The drug has already gained approval in China, where the trial was conducted, and the new survival data strengthen the case for broader adoption. For patients, the practical meaning is straightforward: a treatment option that extends life by a meaningful margin in a disease where every month matters.
What remains to be seen is how quickly and widely ivonescimab will be integrated into standard practice outside China. Regulatory pathways differ by country, and additional trials may be required in Western populations before approval comes through in the United States or Europe. The cost of the drug, manufacturing capacity, and questions about how it performs in different patient populations will all shape its real-world impact. But the ASCO presentation has established one clear fact: in the specific population studied, ivonescimab works better than what came before.
Notable Quotes
Ivonescimab outperformed the standard approach of pairing chemotherapy with a PD-1 inhibitor alone— ASCO trial results
The Hearth Conversation Another angle on the story
Why does a 34 percent reduction in death risk matter so much? That's a number, but what does it mean for someone sitting in an oncologist's office?
It means if you're facing squamous cell lung cancer, your chances of living another year, two years, five years—whatever timeline matters to you—just improved substantially. In a disease where median survival might be measured in months, 34 percent is the difference between hope and despair.
And this drug was controversial before the trial?
Yes. The mechanism was plausible in theory, but there wasn't proof it would work better than what doctors already had. Some researchers thought it was worth pursuing; others thought it was a distraction. Now there's data.
Why did the trial happen in China and not the United States?
Partly because Akeso is a Chinese company, partly because China has been aggressive about running oncology trials quickly. The regulatory environment there allowed them to move faster than they might have elsewhere.
Does a trial in China mean the results apply to American patients?
That's the real question now. The biology of cancer doesn't change by geography, but patient populations can differ—genetics, comorbidities, how advanced the disease is at diagnosis. Regulators will want to see how ivonescimab performs in Western populations before approving it.
So what happens next?
Oncologists start asking for the drug. Patients start asking their doctors about it. Regulatory agencies review the data. And Akeso probably begins planning additional trials or seeking approval pathways in other countries. The momentum is real now.